89bio Inc (NAS:ETNB)

$ 8.855 0.385 (4.55%) Market Cap: 937.83 Mil Enterprise Value: 433.80 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 36/100

89Bio Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023
89Bio Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
89Bio Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
89Bio Inc Topline Results from Phase 2b ENLIVEN Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis - Corporate Call Transcript
Mar 22, 2023
89Bio Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
89Bio Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
89Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
89Bio Inc at Bank of America Healthcare Conference Transcript
May 10, 2022

89Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 08:00PM GMT

Release Date Price: $5 (+4.60%)

Transcript

Ed Arce

H.C. Wainwright & Co. - Analyst

Hello, and welcome to the H.C. Wainwright 24th Annual Global Investment Conference. My name is Ed Arce, and I'm one of the senior biotech analysts here at HCW. And next up, I'm very pleased to have with us the President and CEO of 89bio, Rohan Palekar. Rohan, great to see.

Rohan Palekar

89bio, Inc. - CEO

Great seeing you, Ed. Thanks for having us at the meeting.

Questions & Answers

Ed Arce

H.C. Wainwright & Co. - Analyst

Absolutely. Glad you're here. So let's start by just having you provide a quick overview of the company, your programs, pipeline, and major upcoming milestones.

Rohan Palekar

89bio, Inc. - CEO

Sure. So 89bio is a clinical-stage company focused on cardiometabolic and liver disorders. Our lead program, which we call pegozafermin, is an FGF21 analog, which has been modified to maximize its efficacy and ensure a long-dosing interval.

Now, we think FGF21 and pegozafermin has the potential

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.